| Released | Contributor | Author | Title | Pages | Price |
| 25-Nov-2009 | Pechala's Reports | Lubomir Pechala | NABI BIOPHARMACEUTICALS (NABI=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for NABI | 13 |
$25 |
| 21-Nov-2009 | Standard & Poor's STARS Report |
N/A
| Nabi Biopharmaceuticals | 7 |
$35 |
| 20-Nov-2009 | Pechala's Reports | Lubomir Pechala | NABI BIOPHARMACEUTICALS (NABI=US) 2-weeks forecast | 1 |
$10 |
| 20-Nov-2009 | Pechala's Reports | Frantisek Pechala | NABI BIOPHARMACEUTICALS (NABI=US) 12-months forecast | 1 |
$15 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: NABI BIOPHARM -- NABI | 1 |
$4 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ARQL , CBST , EBS , ENZ , NABI , PDLI -- DRUGS | 3 |
$4 |
0.29% Nasdaq 
Research Reports
